Sanofi finalizes Praluent® (alirocumab) restructuring with Regeneron
Sanofi finalizes Praluent® (alirocumab) restructuring with Regeneron
Paris - April 6, 2020 - Sanofi has finalized the planned restructuring related to Praluent® (alirocumab) with Regeneron Pharmaceuticals, Inc.
Effective April 1, 2020, Sanofi will have sole responsibility for Praluent outside the U.S. Regeneron will have sole responsibility for Praluent in the U.S. The restructuring simplifies the antibody collaboration between the companies, increases efficiency, and streamlines operations for Praluent.
Although each company will have responsibility for supplying Praluent in its respective territory, the companies have entered into agreements to support manufacturing needs in the near term.
Sanofi announced its intent to restructure the antibody collaboration for Praluent and Kevzara® (sarilumab) in December 2019. Sanofi continues to work on assessing the restructuring related to Kevzara given the recently launched U.S. and global clinical programs evaluating Kevzara for patients hospitalized with severe and critical COVID-19 infection.
| About Sanofi Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life |
Sanofi Media Relations Contact Ashleigh Koss Tel.: +1 (908) 981-8745 mr@sanofi.com |
Sanofi Investor Relations Contact Felix Lauscher Tel.: +33 (0)1 53 77 45 45 ir@sanofi.com |
| Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, the risk of global disruption, including pandemics, as well as those risks discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2019. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. |
|
Attachment
\Hugin